Proteomic analysis of psoriatic skin tissue for identification of differentially expressed proteins: Up-regulation of GSTP1, SFN and PRDX2 in psoriatic skin

International Journal of Molecular Medicine

Volumn 28, Issue 5, 2011, Pages 785-792

  Ryu, Joohyun ^a   Park, Sung Goo ^a   Park, Byoung Chul ^a   Choe, Misun ^b   Lee, Kyu Suk ^b   Cho, Jae We ^b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Keimyung University School of Medicine   (South Korea)

Author keywords

Proteomes; Proteomics; Psoriasis

Indexed keywords

ADENOSINE TRIPHOSPHATE SYNTHASE SUBUNIT BETA PROTEIN; ALDEHYDE DEHYDROGENASE; ARGINASE 1; CALGRANULIN B; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; DJ 1 PROTEIN; ENDOPLASMIN PROTEIN; FATTY ACID BINDING PROTEIN; GLUCOSE REGULATED PROTEIN; GLUTATHIONE S TRANSFERASE 1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; HEAT SHOCK PROTEIN 90 BETA; HEAT SHOCK PROTEIN BETA 1; LEUKOCYTE ELASTASE INHIBITOR; MALATE DEHYDROGENASE; PEROXIREDOXIN 2; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN; PROTEIN DISULFIDE ISOMERASE A3; PSORIASIN; PURINE NUCLEOSIDE PHOSPHORYLASE; REACTIVE OXYGEN METABOLITE; SEROTRANSFERRIN; SERPIN B3; SERUM AMYLOID P; SFN PROTEIN; THYMIDINE PHOSPHORYLASE; TUBULIN BETA 2C PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; DATA BASE; EPIDERMIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; PSORIASIS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

14-3-3 PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXONUCLEASES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; PEROXIREDOXINS; PROTEOMICS; PSORIASIS; SKIN; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 80053103198     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.757     Document Type: Article

References (26)

1. Shakery K and Reich K: Psoriasis - clinical picture and current therapy. Med Monatsschr Pharm 32: 335-344, 2009 (In German).
2. Nestle FO, Kaplan DH and Barker J: Psoriasis. N Engl J Med 361: 496-509, 2009.
3. Zippin JH: The genetics of psoriasis. J Drugs Dermatol 8: 414-417, 2009.
4. Zhang XJ, Huang W, Yang S, et al: Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41: 205-210, 2009.
5. Reich A and Szepietowski J: Genetic and immunological aspects of the pathogenesis of psoriasis. Wiad Lek 60: 270-276, 2007 (In Polish).
6. Nickoloff BJ, Xin H, Nestle FO and Qin JZ: The cytokine and chemokine network in psoriasis. Clin Dermatol 25: 568-573, 2007. (Pubitemid 350103656)
7. Murphy M, Kerr P and Grant-Kels JM: The histopathologic spectrum of psoriasis. Clin Dermatol 25: 524-528, 2007. (Pubitemid 350087598)
8. Anderson KS, Wong J, Polyak K, Aronzon D and Enerback C: Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol 160: 325-332, 2009.
9. Wolk K, Witte E, Wallace E, et al: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36: 1309-1323, 2006.
10. Rozieres A, Hennino A and Nicolas JF: TNF alpha in the physiopathology of psoriasis. Ann Dermatol Venereol 133: 174-180, 2006.
11. Shilov VN and Sergienko VI: Oxidative stress in keratinocytes as an etiopathogenetic factor of psoriasis. Bull Exp Biol Med 129: 309-313, 2000.
12. Rashmi R, Rao KS and Basavaraj KH: A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 34: 658-663, 2009.
13. Zhou Q, Mrowietz U and Rostami-Yazdi M: Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 47: 891-905, 2009.
14. Ioannou M, Sourli F, Mylonis I, et al: Increased HIF-1 alpha immunostaining in psoriasis compared to psoriasiform dermatitides. J Cutan Pathol 36: 1255-1261, 2009.
15. Nakai K, Yoneda K, Maeda R, et al: Urinary biomarker of oxidative stress in patients with psoriasis vulgaris and atopic dermatitis. J Eur Acad Dermatol Venereol 23: 1405-1408, 2009.
16. Wojas-Pelc A and Marcinkiewicz J: What is a role of haeme oxygenase-1 in psoriasis? Current concepts of pathogenesis. Int J Exp Pathol 88: 95-102, 2007. (Pubitemid 46570074)
17. Chua RA and Arbiser JL: The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 42: 574-579, 2009.
18. Racz E and Prens EP: Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med 11: e38, 2009.
19. Simonetti O, Lucarini G, Goteri G, et al: VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 19: 751-760, 2006. (Pubitemid 46145039)
20. Krueger JG and Bowcock A: Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 (Suppl 2): S30-S36, 2005.
21. H ermeking H, Lengauer C, Polyak K, et al: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
22. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
23. Samuel T, Weber HO, Rauch P, et al: The G2/M regulator 14-3- 3sigma prevents apoptosis through sequestration of Bax. J Biol Chem 276: 45201-45206, 2001.
24. Briganti S and Picardo M: Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 17: 663-669, 2003. (Pubitemid 37428088)
25. Vanizor Kural B, Orem A, Cimsit G, Yandi YE and Calapoglu M: Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 328: 71-82, 2003. (Pubitemid 36135781)
26. Okayama Y: Oxidative stress in allergic and inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 4: 517-519, 2005.